Altoida, Inc.

New GSA report: 95%+ of #primarycare physicians want to use digital cognitive assessments. Most are still relying on paper tests. Dr. Matt Anderson explores the adoption gap in Episode 1 of Altoida at the Intersection. youtu.be/s7YFw1rpV9Y  #DigitalCognitiveAssessment

Healthcare has done this before. Diabetic retinopathy screening moved from specialty to primary care using digital tools + AI. Neurodegenerative care is next. Watch Altoida at the Intersection Ep1: youtu.be/s7YFw1rpV9Y #DigitalHealth #HealthSystems

Altoida will present new data on scaling early cognitive evaluation beyond specialty centers. As therapies and #bloodbiomarkers enter practice, detection must scale with them. Follow along for updates from Copenhagen. #DigitalHealth #AlzheimersResearch

New era in neurodegenerative care: therapies, #bloodbiomarkers & digital tools are here. Yet millions with #MCI remain undiagnosed. The bottleneck isn’t science. It’s system design. We’re launching #Altoida at the Intersection. Watch Episode 1: youtu.be/s7YFw1rpV9Y

What looks like a simple iPad assessment is a neuroscience-driven platform built on 20+ years of research. #Altoida’s Digital #NeuroMarker Platform captures motor, spatial & speech data to power scalable cognitive infrastructure. youtu.be/0yWka7_HkeE #DigitalHealth #MedTech

We’ll be presenting new data at #AAICNeuroNext on Altoida’s Digital NeuroMarker Platform for identifying MCI. Results show consistent performance across international cohorts, with alignment to established cognitive measures. Looking forward to the discussion.

Our CEO is in Dubai during the #WorldGovernmentSummit to engage with policymakers and global leaders on the future of health systems and technology-enabled care, particularly the role of scalable, validated digital tools in supporting earlier intervention + system sustainability.

We believe the future of brain health pairs digital functional assessment with targeted biology to support earlier understanding and more informed decisions at scale. That’s the direction Altoida is exploring with care models like @Mindspan. Read more: lnkd.in/g9VgjFYQ

We’re proud to co-host a mid-week conversation on what it takes to turn complex signals into real-world impact. If you’re investing in clinically grounded, scalable platforms, join us. Register here: form.jotform.com/253374486642162

Altoida will be in San Francisco for #JPM2026 week. We’re meeting with investors and strategic partners to discuss clinically validated #AI, #digitalbiomarkers and scalable platforms for the next phase of neurodegenerative care. Actively scheduling meetings. Let’s connect.

#CES2026 brings together leaders across tech, healthcare, life sciences + what it takes to turn innovation into real-world impact. Our CEO, Marc Jones, will be discussing what’s next for #BrainHealth infrastructure and how #AI and clinical rigor must move forward together.

At #CTAD2025, our VP of Medical Affairs presents new data from Altoida’s Digital NeuroMarker Platform, a 10-min, AI/AR cognitive assessment designed to detect subtle changes years before legacy tools. Digital biomarkers are redefining early Alzheimer’s detection. #Alzheimers #AI

Nearly 7M Americans live with Alzheimer’s today. #EarlyDetection can change that trajectory. At Altoida, we’re redefining what’s possible in brain health. Get involved: alzfdn.org/alzawarenessmo… #DigitalHealth #NeurologyInnovation

We’re at #BIOEurope to connect on the future of digital brain health. Altoida’s Digital NeuroMarker Platform, a 10-min, AI + AR tool enables multimodal detection of subtle, early cognitive change across neurodegenerative diseases. #AI #DigitalBiomarkers #BrainHealth

On the Health Connective Podcast, CEO Marc Jones shares why diversity in clinical data matters. Altoida’s 800-participant multi-site study showed strong convergence with established scales, validating our Digital NeuroMarker Platform. Listen: healthconnectivetech.com/show/earlier-d…

Our CEO joins biotech and digital health leaders at #BIOFuture on the Healthspan Horizons panel. He will share Altoida’s view that early, precise detection of cognitive decline is key to true healthspan, because brain health drives longevity. #BrainHealth #AI #DigitalDiagnostics

Welcoming Dr. Mona Flores, Dr. Bryan Hansen & Michael Zuendal to Altoida’s Advisory Board as we advance our pivotal FDA study and prepare for global adoption while  redefining precision neurology. Read more: businesswire.com/news/home/2025… #BrainHealth #Alzheimers

New milestone: Pilot feasibility data using Altoida’s AI + AR-powered Digital NeuroMarker Platform in Parkinson’s disease is being presented at MDS 2025. Promising for earlier, more sensitive detection of MCI. Read more: mdsabstracts.org/abstract/pilot… #Parkinsons #AI #BrainHealth

We’re proud to join #MDS2025 where we will present Altoida’s work using our #AI + AR Digital NeuroMarker Platform in #Parkinson’s disease, advancing how clinicians detect & monitor cognitive change. See you there!

On #WorldAlzheimersDay: 55M people live with Alzheimer’s. 79% of Americans say they’d want to know before symptoms interfere with life. People are ready for earlier answers, diagnostics must be too. Read the @Alzheimer’s Association report: alz.org/alzheimers-dem…